| CAS NO: | 2143917-62-6 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 2143917-62-6 |
| 别名 | SM08502 |
| 分子式 | C24H25N7O |
| 分子量 | 427.5 |
| 溶解度 | DMSO : 12.5 mg/mL (29.24 mM; ultrasonic and warming and heat to 60°C) |
| 储存条件 | 4°C, away from moisture and light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research[1]. Cirtuvivint (SM08502) inhibits serine and arginine rich splicing factor (SRSF) phosphorylation and disrupted spliceosome activity, which is associated with inhibition of Wnt pathway-related gene and protein expression. Cirtuvivint induces the generation of splicing variants of Wnt pathway genes, suggesting that its mechanism for inhibition of gene expression includes effects on alternative splicing[1]. Orally administered Cirtuvivint (SM08502) significantly inhibits growth of gastrointestinal tumors and decreased SRSF phosphorylation and Wnt pathway gene expression in xenograft mouse models[1]. [1]. Betty Y Tam, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020 Mar 31;473:186-197. |
m.cnreagent.com